Hiromichi Ebi (H Ebi)

Scopus Author ID Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 28

Top Venues

Cancer science

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

Oncogene

Aichi Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Aichi Cancer Center Feb 01 2018

Japan

Division Chief :: Division of Molecular Therapeutics

Kanazawa University Mar 01 2016 - Jan 31 2018

Japan

Associate Professor :: Division of Medical Oncology, Cancer Research Institute

Kanazawa University Jun 01 2012 - Feb 28 2016

Japan

Assistant Professor :: Division of Medical Oncology, Cancer Research Institute

Publications

Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science 115 (3) (2024)
Hidenori Kitai, Philip H Choi, Yu Chi Yang, Jacob A Boyer, Adele Whaley, Priya Pancholi, Claire Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca Lee, David Wildes, Elisa de Stanchina, Jacqueline A M Smith, Mallika Singh, Neal X Rosen
Combined inhibition of KRAS G12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature communications 15 (1) (2024)
Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Keiji Hirata, Kozo Kataoka, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Yoshinori Kagawa, Kun-Huei Yeh, Saori Mishima, Hiroki Yukami, Koji Ando, Masaaki Miyo, Toshihiro Misumi, Kentaro Yamazaki, Hiromichi Ebi, Kenji Okita, Atsushi Hamabe, Hiroki Sokuoka, Satoshi Kobayashi, George Laliotis, Vasily N Aushev, Shruti Sharma, Adham Jurdi, Minetta C Liu, Alexey Aleshin, Matthew Rabinowitz, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Daisuke Kotani, Masaki Mori, Takayuki Yoshino, Eiji Oki
ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature medicine (2024)
Hidenori Kitai, Philip H Choi, Yu Chi Yang, Jacob A Boyer, Adele Whaley, Priya Pancholi, Claire Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca Lee, David Wildes, Elisa de Stanchina, Jacqueline A M Smith, Mallika Singh, Neal X Rosen
Combined inhibition of KRAS G12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature communications 15 (1) (2024)
Naoko Iida, Mitsuho Imai, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Hiroya Taniguchi, Norio Nonomura, Yu Sunakawa, Manabu Shiozawa, Kentaro Yamazaki, Shogen Boku, Hideaki Bando, Yuichi Shiraishi, Maki Kobayashi, Hiroki Goto, Akihiro Sato, Satoshi Fujii, Takayuki Yoshino, Yoshiaki Nakamura
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science 115 (3) (2024)
Hidenori Kitai, Hiromichi Ebi
Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors. Translational lung cancer research 13 (3) (2024)
Hidenori Kitai, Philip H Choi, Yu Chi Yang, Jacob A Boyer, Adele Whaley, Priya Pancholi, Claire Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca Lee, David Wildes, Elisa de Stanchina, Jacqueline A M Smith, Mallika Singh, Neal X Rosen
Combined inhibition of KRAS G12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature communications 15 (1) (2024)
Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science 115 (3) (2024)
Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science 115 (3) (2024)
Hidenori Kitai, Hiromichi Ebi
Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors. Translational lung cancer research 13 (3) (2024)
Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science (2024)
Hidenori Kitai, Philip H Choi, Yu Chi Yang, Jacob A Boyer, Adele Whaley, Priya Pancholi, Claire Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca Lee, David Wildes, Elisa de Stanchina, Jacqueline A M Smith, Mallika Singh, Neal X Rosen
Combined inhibition of KRAS G12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature communications 15 (1) (2024)
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Shogo Yanase, Yuki Nishioka, Natsumi Kasuga, Rui Yamaguchi, Hiromichi Ebi
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nature cancer (2023)
Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan-Zea Tan, Janina E E Tirnitz-Parker, Jean-Paul Thiery, Hiromichi Ebi, Alan Prem Kumar, Pieter Johan Adam Eichhorn
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. NPJ precision oncology 7 (1) (2023)
Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan-Zea Tan, Janina E E Tirnitz-Parker, Jean-Paul Thiery, Hiromichi Ebi, Alan Prem Kumar, Pieter Johan Adam Eichhorn
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. NPJ precision oncology 7 (1) (2023)
Akimitsu Maeda, Hitoshi Ando, Nobuyuki Katakami, Naoya Hashimoto, Jun-Ichi Morishige, Shoji Fukushima, Akira Okada, Hiromichi Ebi, Masahide Matsuzaki, Hiroji Iwata, Masataka Sawaki
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European journal of clinical pharmacology 78 (8) (2022)
Hiroya Taniguchi, Yoshiaki Nakamura, Daisuke Kotani, Hiroki Yukami, Saori Mishima, Kentaro Sawada, Hiromichi Shirasu, Hiromichi Ebi, Takeharu Yamanaka, Alexey Aleshin, Paul R Billings, Matthew Rabinowitz, Eiji Oki, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Takayuki Yoshino
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer science 112 (7) (2021)
Fumie Nakasuka, Sho Tabata, Takeharu Sakamoto, Akiyoshi Hirayama, Hiromichi Ebi, Tadaaki Yamada, Ko Umetsu, Maki Ohishi, Ayano Ueno, Hisatsugu Goto, Masahiro Sugimoto, Yasuhiko Nishioka, Yasuhiro Yamada, Masaru Tomita, Atsuo T Sasaki, Seiji Yano, Tomoyoshi Soga
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Communications biology 4 (1) (2021)
Yoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Kentaro Sawada, Hiroya Taniguchi, Nozomu Fuse, Shogo Nomura, Makoto Fukui, Seiko Matsuda, Yasutoshi Sakamoto, Hiroshi Uchigata, Kana Kitajima, Naomi Kuramoto, Takashi Asakawa, Steve Olsen, Justin I Odegaard, Akihiro Sato, Satoshi Fujii, Atsushi Ohtsu, Takayuki Yoshino
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature medicine 27 (11) (2021)
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Hiromichi Ebi
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers 13 (20) (2021)
Hiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, Takeshi Kato, Satoshi Fujii, Hiromichi Ebi, Manabu Shiozawa, Satoshi Yuki, Toshiki Masuishi, Ken Kato, Naoki Izawa, Toshikazu Moriwaki, Eiji Oki, Yoshinori Kagawa, Tadamichi Denda, Tomohiro Nishina, Akihito Tsuji, Hiroki Hara, Taito Esaki, Tomohiro Nishida, Hiasto Kawakami, Yasutoshi Sakamoto, Izumi Miki, Wataru Okamoto, Kentaro Yamazaki, Takayuki Yoshino
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer science 112 (1) (2020)
Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan-Zea Tan, Rui Yamaguchi, Hiromichi Ebi
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (22) (2020)
Hiromichi Ebi, Hideaki Bando, Hiroya Taniguchi, Yu Sunakawa, Yoshinaga Okugawa, Yutaka Hatanaka, Waki Hosoda, Kensuke Kumamoto, Kaname Nakatani, Kentaro Yamazaki
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer science 111 (10) (2020)
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R Parikh, Hideaki Bando, Emily E Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N Thant, Elisa de Stanchina, Neal X Rosen, Ryan B Corcoran, Takayuki Yoshino, Zhan Yao, Hiromichi Ebi
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (23) (2019)
Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T Jakubik, Laura E Henderson, Leah J Damon, Daria Timonina, Ioannis Sanidas, Christopher J Pinto, Mari A Mino-Kenudson, James R Stone, Nicholas J Dyson, Leif W Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H Benes, Jeffrey A Engelman, Dejan Juric
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer discovery 10 (1) (2019)
Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L Lochmann, Yoshiko Murakami, Neha U Patel, Jungoh Ham, Bin Hu, Krista M Powell, Colin M Coon, Brad E Windle, Yuko Oya, Jennifer E Koblinski, Hisashi Harada, Joel D Leverson, Andrew J Souers, Aaron N Hata, Sosipatros Boikos, Yasushi Yatabe, Hiromichi Ebi, Anthony C Faber
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (22) (2018)
Hiroshi Kotani, Yuta Adachi, Hidenori Kitai, Shuta Tomida, Hideaki Bando, Anthony C Faber, Takayuki Yoshino, Dominic C Voon, Seiji Yano, Hiromichi Ebi
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene 37 (13) (2018)
H Kotani, Hiromichi Ebi, H Kitai, S Nanjo, K Kita, T G Huynh, A Ooi, A C Faber, M Mino-Kenudson, S Yano
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35 (27) (2015)

Hiromichi Ebi.css-eqlu8i{font-size:small;padding-left:4px;} (H Ebi)

Publication Activity (10 Years)

Top Topics

Top Venues

Hiromichi Ebi (H Ebi)